Document complet  |  Dérouler chapitre  |  Etendre sommaire  |  Version HTML imprimable
Counterfeit Drugs. Guidelines for the development of measures to combat counterfeit drugs
(1999; 61 pages) [French] [Spanish] Voir le document au format PDF
Abrégé
These guidelines respond to the WHA requests: They are aimed to provide guidance to Member States in developing their own national measures to combat counterfeiting of drugs. The guidelines provide an overview of the problem and factors contributing to the counterfeiting of drugs. They outline also the steps to be followed in developing national strategies as well the specific measures to be considered in combating counterfeit drugs. Issues such as, approaches to country studies, inspection of suspected counterfeit drugs, screening of potentially counterfeit products and training of human resources are also dealt with in the guidelines.
Table des matières
Afficher le documentExecutive Summary
Ouvrir ce répertoire et afficher son contenu1. Introduction
Afficher le document2. Overview of the problem
Afficher le document3. Impact on public health
Afficher le document4. Factors facilitating counterfeiting
Ouvrir ce répertoire et afficher son contenu5. Developing national strategies
Ouvrir ce répertoire et afficher son contenu6. Specific measures
Ouvrir ce répertoire et afficher son contenu7. Assessment of the problem at the national level
Ouvrir ce répertoire et afficher son contenu8. Inspection when pharmaceutical products are suspected to be counterfeit, spurious or substandard
Ouvrir ce répertoire et afficher son contenu9. Test methods
Ouvrir ce répertoire et afficher son contenu10. Developing training programmes: inspection and examination of counterfeit pharmaceuticals
Afficher le document11. Conclusion
Afficher le documentReferences
Afficher le documentSelected further reading
Afficher le documentAcknowledgements
Afficher le documentGlossary
 

Counterfeit Drugs. Guidelines for the development of measures to combat counterfeit drugs

Guidelines for the development
of measures to combat
counterfeit drugs

Department of Essential Drugs and
Other Medicines
World Health Organization
Geneva, Switzerland

ORGANISATION MONDIALE DE LA SANTE

WHO/EDM/QSM/99.1
DISTR: GENERAL
ORIGINAL: ENGLISH

This document has been prepared under the auspices of the DMP-DAP Joint Project on Counterfeit Drugs which was administered by the World Health Organization Division of Drug Management and Policies (DMP) and the Action Programme on Essential Drugs (DAP) from 1995 to 1997. With effect from January 1999, the Department of Essential Drugs and Other Medicines Department (EDM) includes the former DAP and most components of DMP.

©World Health Organization (1999)

This document is not a formal publication of the World Health Organization (WHO) and all rights are reserved by the Organization. The document may, however, be freely reviewed, abstracted, reproduced, translated, in part or in whole, but not for sale nor for use in conjunction with commercial purposes.

The view expressed in documents by named authors are solely the responsibility of those authors.

 

vers la section suivante
 
 
Le Portail d'information - Médicaments essentiels et produits de santé a été conçu et est maintenu par l'ONG Human Info. Dernière mise à jour: le 25 juin 2014